Bedoya, focused and passionate, talks about putting consumers first
Federal Trade Commission member Alvaro Bedoya just reached his six-month work anniversary. The former Senate staffer and Georgetown University professor arrived at a time of incredible activity at the FTC. It issued an advanced notice of proposed...
Some hits and a miss in Section 5 policy statement
The diplomat Talleyrand, who represented post-Napoleonic France at the make-or-break Congress of Vienna, cautioned his staff to move only in measured steps: “Above all,” he said, “no zeal.” This would have been equally good advice for the Federal Trade Commission’s policy statement on Section 5...
Current Issue: 796
FTC in the driver’s seat on vehicle-industry regulation
The Federal Trade Commission has been given enhanced powers to regulate the $620 billion car-sales and finance industry under the Dodd-Frank Wall Street Reform and Consumer Protection Act---and it...
Is innovation an antitrust innovation?
Are the effects on innovation becoming an important new criterion in government antitrust deliberations?
FTC’s Rosch predicts trouble with ACOs
Health-care providers who want to participate in the Medicare Shared Savings Program by joining together to form Accountable Care Organizations will need to police themselves carefully to avoid...
FTC sides with dental hygienists in Maine
The FTC staff told the Maine Board of Dental Examiners that its proposed rules on dental hygienists could restrict a pilot project designed to expand access to dental services in areas where no...
Second look at Lundbeck
An eight-day bench hearing held in Minneapolis, Minn., in December 2009, could have far-reaching legal implications for antitrust law, particularly regarding future pharmaceutical cases. It could...
Gilead Science vies for purchase of Pharmasset
Biotechnology firm Gilead Sciences, the leading maker of HIV drugs, has announced its plans to acquire a rival firm, Pharmasset, for $11 billion.